Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early clinical studies, recent reports detailing a modified dosing regimen of GO can be safely combined with induction chemotherapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cathy C, Yan, Zhengming, Pascual, Bernadette, Jackson-Fisher, Amy, Huang, Donghui Stephen, Zong, Qing, Elliott, Mark, Fan, Conglin, Huser, Nanni, Lee, Joseph, Sung, Matthew, Sapra, Puja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702869/
https://www.ncbi.nlm.nih.gov/pubmed/29172076
http://dx.doi.org/10.1016/j.neo.2017.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702869/
https://www.ncbi.nlm.nih.gov/pubmed/29172076
http://dx.doi.org/10.1016/j.neo.2017.10.008

Ejemplares similares